Amylyx Pharmaceuticals, a fast-rising biotech company that went public last month, created the role of chief legal officer and filled it with Gina Mazzariello, who has more than two decades of legal experience in the health care industry.

Cambridge, Massachusetts-based Amylyx, founded in 2013, is a clinical-stage company that aims to treat amyotrophic lateral sclerosis, also known as Lou Gehrig’s disease, by addressing the death of neurons. It raised $190 million in its initial public offering and now has a market value of $1.7 billion.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]